Using population-wide administrative and laboratory data to estimate type- and subtype-specific influenza vaccine effectiveness: a surveillance protocol

Scott, Allison Nicole; Buchan, Sarah A; Kwong, Jeffrey C; Drews, Steven J; Simmonds, Kimberley A; Svenson, Lawrence W

TAB 150MG 02377705 ERLOTINIB HCL TABLET 100MG 02377713 ERLOTINIB HCL TABLET 150MG 02434407 IBRUTINIB CAP 140MG 09857447 IMATINIB MESYLATE TAB 100MG 02388006 RUXOLITINIB TAB 5MG 02388014 RUXOLITINIB TAB 15MG 02388022 RUXOLITINIB TAB 20MG 02409658 TRAMETINIB RECOMBINANT TAB 2MG 01926438 ASPARAGINASE INJ PWS 10MU 02389649 AXITINIB TAB 5MG 02389630 AXITINIB TAB FC 1MG 02262452 BORTEZOMIB IV PWS 3.5MG 00521183 DACARBAZINE IV PWS 200MG/VIAL 02154854 DACARBAZINE IV PWS 200MG 02248676 GEFITINIB TAB 250MG 02244725 IMATINIB MESYLATE CAP 100MG 02399806 IMATINIB MESYLATE FC TAB 100MG 02355337 IMATINIB MESYLATE TAB 100MG 02355345 IMATINIB MESYLATE TAB 400MG 02397285 IMATINIB MESYLATE TAB 100MG 02397293 IMATINIB MESYLATE TAB 400MG 02399814 IMATINIB MESYLATE TAB 400MG 02431114 IMATINIB MESYLATE TAB 100MG 02431122 IMATINIB MESYLATE TAB 400MG 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 F o r p e e r r e v i e w o n l y 22 DIN Drug Name Route of Administration Strength 09857448 IMATINIB MESYLATE TAB 400MG 02253275 IMATINIB MESYLATE TAB 100MG 02253283 IMATINIB MESYLATE TAB 400MG 02326442 LAPATINIB DITOSYLATE TAB 250MG 02315874 NILOTINIB CAP 200MG 02368250 NILOTINIB CAP 150MG 02352303 PAZOPANIB HCL TAB 200MG 00012750 Isolates will be considered eligible for inclusion in the analysis if they met all of the following criteria: a valid 160 PHN is recorded, the isolate is not from a resident of a long-term care facility, the isolate was collected at 161 least four weeks after the initiation of the public influenza vaccination program, and the isolate was collected 162 during the influenza season, as determined using the method recommended by the WHO r [19-21].